Advertisement

Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach

Published:August 19, 2017DOI:https://doi.org/10.1016/j.ejim.2017.08.019

      Highlights

      • Autoimmune endocrinopathies are frequent complications of cancer immunotherapy.
      • The mechanism relies on the activation of the immune system.
      • The most common endocrinopathies are autoimmune thyroiditis and hypophysitis.
      • Early detection and appropriate management is crucial to avoid complications.
      • Pituitary and thyroid dysfunctions are associated with improved outcomes.

      Abstract

      Cancer immunotherapy has proven to be effective in a wide variety of tumors. The use of immune checkpoint blocking monoclonal antibodies has become a standard treatment regimen in some of them as advanced melanoma. However, given the mechanism of action, its use may be associated with immune-related adverse events that may complicate the clinical course and prognosis of patients. Among these are autoimmune endocrine adverse effects, such as hypophysitis, hypo and hyperthyroidism, and adrenal insufficiency. This review focuses on the most relevant and new aspects related to the incidence, clinical presentation, diagnosis and treatment of these adverse effects associated with different types of immune checkpoint inhibitors in cancer immunotherapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ott P.A.
        • Hodi F.S.
        • Robert C.
        CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
        Clin Cancer Res. 2013; 19: 5300-5309
        • Ito A.
        • Kondo S.
        • Tada K.
        • Kitano S.
        Clinical development of immune checkpoint inhibitors.
        Biomed Res Int. 2015; 605478https://doi.org/10.1155/2015/605478
        • Bertrand A.
        • Kostine M.
        • Barnetche T.
        • Truchetet M.E.
        • Schaeverbeke T.
        Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
        BMC Med. 2015; 13: 211
        • Costa R.
        • Carneiro B.A.
        • Agulnik M.
        • Rademaker A.W.
        • Pai S.G.
        • Villaflor V.M.
        • et al.
        Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
        Oncotarget. 2017; 8: 8910-8920
        • Voskens C.J.
        • Goldinger S.M.
        • Loquai C.
        • Robert C.
        • Kaehler K.C.
        • Berking C.
        • et al.
        The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
        PLoS One. 2013; 8e53745
        • Torino F.
        • Corsello S.M.
        • Salvatori R.
        Endocrinological side-effects of immune checkpoint inhibitors.
        Curr Opin Oncol. 2016; 4: 278-287
        • Joshi M.N.
        • Whitelaw B.C.
        • Palomar M.T.
        • Wu Y.
        • Carroll P.V.
        Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
        Clin Endocrinol. 2016; 3: 331-339
        • Marrone K.A.
        • Ying W.
        • Naidoo J.
        Immune-related adverse events from immune checkpoint inhibitors.
        Clin Pharmacol Ther. 2016; 3: 242-251
        • Spain L.
        • Diem S.
        • Larkin J.
        Management of toxicities of immune checkpoint inhibitors.
        Cancer Treat Rev. 2016; 44: 51-60
        • Faje A.
        Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
        Pituitary. 2016; 1: 82-92
        • Byun D.J.
        • Wolchok J.D.
        • Rosenberg L.M.
        • Girotra M.
        Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies.
        Nat Rev Endocrinol. 2017; 13: 195-207
        • Abdel-Rahman O.
        • ElHalawani H.
        • Fouad M.
        Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
        Future Oncol. 2016; 3: 413-425
        • Peterson J.J.
        • Steele-Moses S.K.
        Update on new therapies with immune checkpoint inhibitors.
        Clin J Oncol Nurs. 2016; 4: 405-410
        • Ma W.
        • Gilligan B.M.
        • Yuan J.
        • Li T.
        Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
        J Hematol Oncol. 2016; 2747
        • Hodi F.S.
        • O'Day S.J.
        • McDermott D.F.
        • Weber R.W.
        • Sosman J.A.
        • Haanen J.B.
        • et al.
        Improved survival with ipilimumab in patients with metastatic melanoma.
        N Engl J Med. 2010; 8: 711-723
        • Maio M.
        • Grob J.J.
        • Aamdal S.
        • Bondarenko I.
        • Robert C.
        • Thomas L.
        • et al.
        Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
        J Clin Oncol. 2015; 10: 1191-1196
        • Eggermont A.M.
        • Chiarion-Sileni V.
        • Grob J.J.
        • Dummer R.
        • Wolchok J.D.
        • Schmidt H.
        • et al.
        Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.
        N Engl J Med. 2016; 375: 1845-1855
        • Atkins M.B.
        • Clark J.I.
        • Quinn D.I.
        Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
        Ann Oncol. 2017; https://doi.org/10.1093/annonc/mdx151
        • Ribas A.
        • Kefford R.
        • Marshall M.A.
        • Punt C.J.
        • Haanen J.B.
        • Marmol M.
        • et al.
        Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
        J Clin Oncol. 2013; 5: 616-622
        • Calabro L.
        • Morra A.
        • Fonsatti E.
        • Cutaia O.
        • Fazio C.
        • Annesi D.
        • et al.
        Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
        Lancet Respir Med. 2015; 4: 301-309
        • Comin-Anduix B.
        • Escuin-Ordinas H.
        • Ibarrondo F.J.
        Tremelimumab: research and clinical development.
        Onco Targets Ther. 2016; : 1767-1776
        • Ribas A.
        • Puzanov I.
        • Dummer R.
        • Schadendorf D.
        • Hamid O.
        • Robert C.
        • et al.
        Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
        Lancet Oncol. 2015; 8: 908-918
        • Robert C.
        • Schachter J.
        • Long G.V.
        • Arance A.
        • Grob J.J.
        • Mortier L.
        • et al.
        Pembrolizumab versus Ipilimumab in Advanced Melanoma.
        N Engl J Med. 2015; 26: 2521-2532
        • Reck M.
        • Bondarenko I.
        • Luft A.
        • Serwatowski P.
        • Barlesi F.
        • Chacko R.
        • et al.
        Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
        Ann Oncol. 2013; 1: 75-83
        • Ferris R.L.
        • Blumenschein Jr., G.
        • Fayette J.
        • Guigay J.
        • Colevas A.D.
        • Licitra L.
        • et al.
        Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
        N Engl J Med. 2016; 375: 1856-1867
        • Armand P.
        • Nagler A.
        • Weller E.A.
        • Devine S.M.
        • Avigan D.E.
        • Chen Y.B.
        • et al.
        Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
        J Clin Oncol. 2013; 33: 4199-4206
        • Westin J.R.
        • Chu F.
        • Zhang M.
        • Fayad L.E.
        • Kwak L.W.
        • Fowler N.
        • et al.
        Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
        Lancet Oncol. 2014; 1: 69-77
        • Hodi F.S.
        • Chesney J.
        • Pavlick A.C.
        • Robert C.
        • Grossmann K.F.
        • McDermott D.F.
        • et al.
        Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
        Lancet Oncol. 2016; 11: 1558-1568
        • Kirchberger M.C.
        • Hauschild A.
        • Schuler G.
        • Heinzerling L.
        Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
        Eur J Cancer. 2016; 65: 182-184
        • Faje A.T.
        • Sullivan R.
        • Lawrence D.
        • Tritos N.A.
        • Fadden R.
        • Klibanski A.
        • et al.
        Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
        J Clin Endocrinol Metab. 2014; 11: 4078-4085
        • Bellastella G.
        • Maiorino M.I.
        • Bizzarro A.
        • Giugliano D.
        • Esposito K.
        • Bellastella A.
        • et al.
        Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects.
        Pituitary. 2016; 6: 625-642
        • Phan G.Q.
        • Yang J.C.
        • Sherry R.M.
        • Hwu P.
        • Topalian S.L.
        • Schwartzentruber D.J.
        • et al.
        Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
        Proc Natl Acad Sci U S A. 2003; 14: 8372-8377
        • Juszczak A.
        • Gupta A.
        • Karavitaki N.
        • Middleton M.R.
        • Grossman A.B.
        Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
        Eur J Endocrinol. 2012; 1: 1-5
        • Postow M.A.
        • Luke J.J.
        • Bluth M.J.
        • Ramaiya N.
        • Panageas K.S.
        • Lawrence D.P.
        • et al.
        Ipilimumab for patients with advanced mucosal melanoma.
        Oncologist. 2013; 6: 726-732
        • Blansfield J.A.
        • Beck K.E.
        • Tran K.
        • Yang J.C.
        • Hughes M.S.
        • Kammula U.S.
        • et al.
        Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
        J Immunother. 2005; 6: 593-598
        • Maker A.V.
        • Yang J.C.
        • Sherry R.M.
        • Topalian S.L.
        • Kammula U.S.
        • Royal R.E.
        • et al.
        Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
        J Immunother. 2006; 4: 455-463
        • Downey S.G.
        • Klapper J.A.
        • Smith F.O.
        • Yang J.C.
        • Sherry R.M.
        • Royal R.E.
        • et al.
        Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
        Clin Cancer Res. 2007; 13: 6681-6688
        • Carpenter K.J.
        • Murtagh R.D.
        • Lilienfeld H.
        • Weber J.
        • Murtagh F.R.
        Ipilimumab-induced hypophysitis: MR imaging findings.
        AJNR Am J Neuroradiol. 2009; 9: 1751-1753
        • Dillard T.
        • Yedinak C.G.
        • Alumkal J.
        • Fleseriu M.
        Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
        Pituitary. 2010; 1: 29-38
        • Min L.
        • Vaidya A.
        • Becker C.
        Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series.
        Endocr Pract. 2012; 3: 351-355
        • de Hollanda A.
        • Aranda G.B.
        • Mora M.
        • Gaba L.
        • Halperin I.
        Ipilimumab, a cause of autoimmune hypophysitis.
        Endocrinol Nutr. 2013; 10: 604-606
        • Chodakiewitz Y.
        • Brown S.
        • Boxerman J.L.
        • Brody J.M.
        • Rogg J.M.
        Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
        Clin Neurol Neurosurg. 2014; : 125-130
        • Marlier J.
        • Cocquyt V.
        • Brochez L.
        • Van Belle S.
        • Kruse V.
        Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
        Endocrine. 2014; 3: 878-883
        • Ryder M.
        • Callahan M.
        • Postow M.A.
        • Wolchok J.
        • Fagin J.A.
        Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
        Endocr Relat Cancer. 2014; 2: 371-381
        • Albarel F.
        • Gaudy C.
        • Castinetti F.
        • Carre T.
        • Morange I.
        • Conte-Devolx B.
        • et al.
        Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
        Eur J Endocrinol. 2015; 172: 195-204
        • Iwama S.
        • De Remigis A.
        • Callahan M.K.
        • Slovin S.F.
        • Wolchok J.D.
        • Caturegli P.
        Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
        Sci Transl Med. 2014; 6230ra45
        • Tomasini P.
        • Khobta N.
        • Greillier L.
        • Barlesi F.
        Ipilimumab: its potential in non-small cell lung cancer.
        Ther Adv Med Oncol. 2012; 2: 43-50
        • Yang J.C.
        • Hughes M.
        • Kammula U.
        • Royal R.
        • Sherry R.M.
        • Topalian S.L.
        • et al.
        Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
        J Immunother. 2007; 8: 825-830
        • Min L.
        • Hodi F.S.
        • Giobbie-Hurder A.
        • Ott P.A.
        • Luke J.J.
        • Donahue H.
        • et al.
        Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
        Clin Cancer Res. 2015; 4: 749-755
        • Iglesias P.
        • Soria A.
        • Diez J.J.
        Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer.
        Med Clin (Barc). 2015; 6: 264-268
        • Horvat T.Z.
        • Adel N.G.
        • Dang TO
        • Momtaz P.
        • Postow M.A.
        • Callahan M.K.
        • et al.
        Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.
        J Clin Oncol. 2015; 28: 3193-3198
        • Eggermont A.M.
        • Chiarion-Sileni V.
        • Grob J.J.
        • Dummer R.
        • Wolchok J.D.
        • Schmidt H.
        • et al.
        Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
        Lancet Oncol. 2015; 5: 522-530
        • Brilli L.
        • Danielli R.
        • Ciuoli C.
        • Calabro L.
        • Di Giacomo A.M.
        • Cerase A.
        • et al.
        Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
        Endocrine. 2017 Apr 12; https://doi.org/10.1007/s12020-017-1289-2
        • Ascierto P.A.
        • Del Vecchio M.
        • Robert C.
        • Mackiewicz A.
        • Chiarion-Sileni V.
        • Arance A.
        • et al.
        Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
        Lancet Oncol. 2017; 5: 611-622
        • Attia P.
        • Phan G.Q.
        • Maker A.V.
        • Robinson M.R.
        • Quezado M.M.
        • Yang J.C.
        • et al.
        Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
        J Clin Oncol. 2005; 25: 6043-6053
        • Corsello S.M.
        • Barnabei A.
        • Marchetti P.
        • De Vecchis L.
        • Salvatori R.
        • Torino F.
        Endocrine side effects induced by immune checkpoint inhibitors.
        J Clin Endocrinol Metab. 2013; 4: 1361-1375
        • Ribas A.
        • Comin-Anduix B.
        • Chmielowski B.
        • Jalil J.
        • de la Rocha P.
        • McCannel T.A.
        • et al.
        Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
        Clin Cancer Res. 2009; 19: 6267-6276
        • Millward M.
        • Underhill C.
        • Lobb S.
        • McBurnie J.
        • Meech S.J.
        • Gomez-Navarro J.
        • et al.
        Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
        Br J Cancer. 2013; 10: 1998-2004
        • Okano Y.
        • Satoh T.
        • Horiguchi K.
        • Toyoda M.
        • Osaki A.
        • Matsumoto S.
        • et al.
        Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
        Endocr J. 2016; 10: 905-912
        • Ishikawa M.
        • Oashi K.
        Case of hypophysitis caused by nivolumab.
        J Dermatol. 2017; 44: 109-110
        • Topalian S.L.
        • Hodi F.S.
        • Brahmer J.R.
        • Gettinger S.N.
        • Smith D.C.
        • McDermott D.F.
        • et al.
        Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
        N Engl J Med. 2012; 26: 2443-2454
        • Robert C.
        • Long G.V.
        • Brady B.
        • Dutriaux C.
        • Maio M.
        • Mortier L.
        • et al.
        Nivolumab in previously untreated melanoma without BRAF mutation.
        N Engl J Med. 2015; 4: 320-330
        • Nishimura H.
        • Honjo T.
        PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.
        Trends Immunol. 2001; 5: 265-268
        • Larkin J.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • Grob J.J.
        • Cowey C.L.
        • Lao C.D.
        • et al.
        Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma.
        N Engl J Med. 2015; 1: 23-34
        • Buchbinder E.I.
        • Desai A.
        CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition.
        Am J Clin Oncol. 2016; 39: 98-106
        • Laurent S.
        • Queirolo P.
        • Boero S.
        • Salvi S.
        • Piccioli P.
        • Boccardo S.
        • et al.
        The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production.
        J Transl Med. 2013; 11: 108https://doi.org/10.1186/1479-5876-11-108
        • Mei Y.
        • Bi W.L.
        • Greenwald N.F.
        • Du Z.
        • Agar N.Y.
        • Kaiser U.B.
        • et al.
        Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
        Oncotarget. 2016; 7: 76565-76576
        • Weber J.S.
        Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.
        Am Soc Clin Oncol Educ Book. 2012; : 174-177https://doi.org/10.14694/EdBook_AM.2012.32.174
        • Nallapaneni N.N.
        • Mourya R.
        • Bhatt V.R.
        • Malhotra S.
        • Ganti A.K.
        • Tendulkar K.K.
        Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
        J Natl Compr Cancer Netw. 2014; 8: 1077-1081
        • Barnard Z.R.
        • Walcott B.P.
        • Kahle K.T.
        • Nahed B.V.
        • Coumans J.V.
        Hyponatremia associated with Ipilimumab-induced hypophysitis.
        Med Oncol. 2012; 1: 374-377
        • Singh D.
        • Hsu C.C.
        • Kwan G.N.
        • Bhuta S.
        Ipilimumab-induced hypophysitis and ileocolitis: serial pituitary MRI findings.
        Neurol India. 2017; 1: 165-166
        • Marques P.
        • Grossman A.
        Ipilimumab-induced autoimmune hypophysitis: diagnostic and management challenges illustrated by a clinical case.
        Acta Medica Port. 2015; 6: 775-779
        • de Filette J.
        • Jansen Y.
        • Schreuer M.
        • Everaert H.
        • Velkeniers B.
        • Neyns B.
        • et al.
        Incidence of thyroid-related adverse events in melanoma patients treated with Pembrolizumab.
        J Clin Endocrinol Metab. 2016; 11: 4431-4439
        • Morganstein D.L.
        • Lai Z.
        • Spain L.
        • Diem S.
        • Levine D.
        • Mace C.
        • et al.
        Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
        Clin Endocrinol. 2017; 4: 614-620
        • Ribas A.
        • Camacho L.H.
        • Lopez-Berestein G.
        • Pavlov D.
        • Bulanhagui C.A.
        • Millham R.
        • et al.
        Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
        J Clin Oncol. 2005; 35: 8968-8977
        • Orlov S.
        • Salari F.
        • Kashat L.
        • Walfish P.G.
        Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
        J Clin Endocrinol Metab. 2015; 5: 1738-1741
        • Min L.
        • Vaidya A.
        • Becker C.
        Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.
        Eur J Endocrinol. 2011; 2: 303-307
        • Borodic G.
        • Hinkle D.M.
        • Cia Y.
        Drug-induced graves disease from CTLA-4 receptor suppression.
        Ophthal Plast Reconstr Surg. 2011; 4: e87-8
        • Azmat U.
        • Liebner D.
        • Joehlin-Price A.
        • Agrawal A.
        • Nabhan F.
        Treatment of Ipilimumab induced Graves' disease in a patient with metastatic melanoma.
        Case Rep Endocrinol. 2016; 2016: 2087525https://doi.org/10.1155/2016/2087525
        • McMillen B.
        • Dhillon M.S.
        • Yong-Yow S.
        A rare case of thyroid storm.
        BMJ Case Rep. 2016 Apr 18; 201610.1136/bcr-2016-214603https://doi.org/10.1136/bcr-2016-214603
        • Khan U.
        • Rizvi H.
        • Sano D.
        • Chiu J.
        • Hadid T.
        Nivolumab induced myxedema crisis.
        J Immunother Cancer. 2017; 5 ([eCollection 2017]): 13https://doi.org/10.1186/s40425-017-0213-x
        • Osorio J.C.
        • Ni A.
        • Chaft J.E.
        • Pollina R.
        • Kasler M.K.
        • Stephens D.
        • et al.
        Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
        Ann Oncol. 2017; 3: 583-589
        • Min L.
        • Ibrahim N.
        Ipilimumab-induced autoimmune adrenalitis.
        Lancet Diabetes Endocrinol. 2013; 1e15https://doi.org/10.1016/S2213-8587(13)70031-7
        • Trainer H.
        • Hulse P.
        • Higham C.E.
        • Trainer P.
        • Lorigan P.
        Hyponatraemia secondary to nivolumab-induced primary adrenal failure.
        Endocrinol Diabetes Metab Case Rep. 2016; 16 ([Epub 2016 Nov 1])
        • Bacanovic S.
        • Burger I.A.
        • Stolzmann P.
        • Hafner J.
        • Huellner M.W.
        Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET/CT.
        Clin Nucl Med. 2015; 11: e518-9
        • Hughes J.
        • Vudattu N.
        • Sznol M.
        • Gettinger S.
        • Kluger H.
        • Lupsa B.
        • et al.
        Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.
        Diabetes Care. 2015; 4: e55-7
        • Hofmann L.
        • Forschner A.
        • Loquai C.
        • Goldinger S.M.
        • Zimmer L.
        • Ugurel S.
        • et al.
        Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
        Eur J Cancer. 2016; : 190-209
        • Okamoto M.
        • Okamoto M.
        • Gotoh K.
        • Masaki T.
        • Ozeki Y.
        • Ando H.
        • et al.
        Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
        J Diabetes Investig. 2016; 6: 915-918
        • Miyoshi Y.
        • Ogawa O.
        • Oyama Y.
        Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes.
        Tohoku J Exp Med. 2016; 2: 155-158
        • Teramoto Y.
        • Nakamura Y.
        • Asami Y.
        • Imamura T.
        • Takahira S.
        • Nemoto M.
        • et al.
        Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
        J Dermatol. 2016; 44: 605-606
        • Chae Y.K.
        • Chiec L.
        • Mohindra N.
        • Gentzler R.
        • Patel J.
        • Giles F.
        A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
        Cancer Immunol Immunother. 2017; 1: 25-32
        • Lowe J.R.
        • Perry D.J.
        • Salama A.K.
        • Mathews C.E.
        • Moss L.G.
        • Hanks B.A.
        Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.
        J Immunother Cancer. 2016; 4 ([eCollection 2016]): 89https://doi.org/10.1186/s40425-016-0196-z
        • Win M.A.
        • Thein K.Z.
        • Qdaisat A.
        • Yeung S.J.
        Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.
        Am J Emerg Med. 2017; 351039.e5-7